Derek DiRocco - 17 Jun 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Reporting relationship: Director
Issuer ticker: ACRV
Reported as of: 17 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Jun 2026, 16:09:10 UTC
Prior SEC filing: 20 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam D. Levy, Attorney-in-Fact

Key filing fact

Derek DiRocco filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 22 Jun 2026.

Key facts

This page summarizes Derek DiRocco's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Jun 2026, 16:09.

Change

Previous filing in this sequence was filed on 20 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001792061 Primary reporting owner

DiRocco Derek

Relationship: Director
Address: C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN
Signature: /s/ Adam D. Levy, Attorney-in-Fact
Signature date: 22 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACRV transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +20,275
Change %
Price: $0.000000^*
Shares after: 20,275
Date: 17 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,275
Exercise price: $1.52
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

Footnote F2

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.